Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes.

/by

Authors: Ethan B. Russo
Cannabis and Cannabinoid Research, 1 July 2016
—
Medicine continues to struggle in its approaches to numerous common subjective pain syndromes that lack objective signs and remain treatment resistant. Foremost among these are migraine, fibromyalgia, and irritable bowel syndrome, disorders that may overlap in their affected p…

Read more

Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study.

/by

Authors: Itay Lotan, Therese Treves, Yaniv Roditi, Ruth Djaldetti
Clinical Neuropharmacology, March-April 2014
—
OBJECTIVE: The use of cannabis as a therapeutic agent for various medical conditions has been well documented. However, clinical trials in patients with Parkinson disease (PD) have yielded conflicting results. The aim of the present open-label observational study was to assess…

Read more

Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.

/by

Authors: Antonio Waldo Zuardi
Brazilian Journal of Psychiatry, September 2008
—
OBJECTIVE: The aim of this review is to describe the historical development of research on cannabidiol. METHOD: This review was carried out on reports drawn from Medline, Web of Science and SciELO. DISCUSSION: After the elucidation of the chemical structure of cannabidiol in 1…

Read more

Survey on cannabis use in Parkinson’s disease: subjective improvement of motor symptoms.

/by

Authors: Katerina Venderova, Evzen Růzicka, Viktor Vorısek, Peter Visnovsky
Movement Disorders, September 2004
—
An anonymous questionnaire sent to all patients attending the Prague Movement Disorder Centre revealed that 25% of 339 respondents had taken cannabis and 45.9% of these described some form of benefit.

Read more